IDS Form PTO/SB/08: Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				*Application Number*	10/517,812
				Filing Date	December 14, 2004
				First Named Inventor	Harald BREIVIK et al.
(Use as many sheets as necessary)				*Art Unit*	1621
				Examiner Name	Deborah D. CARR
Sheet	1	of	3	*Attorney Docket Number*	10260.0006-00000

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS					
Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] *(if known)*	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1.	US-2,126,467	08-09-1938	Hickman et al.	
	2.	US-3,082,228	03-19-1963	Sutherland	
	3.	US-4,554,107	11-19-1985	Takao	
	4.	US-5,106,542	04-21-1992	Traitler et al.	
	5.	US-5,243,046	09-07-1993	Traitler et al.	
	6.	US-5,340,602	08-23-1994	Hoche	
	7.	US-5,374,751	12-20-1994	Cheng et al.	
	8.	US-5,792,795	08-11-1998	Buser et al.	
	9.	US-5,948,818	09-07-1999	Buser et al.	
		US-			
		US-			

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3] Number[4] Kind Code[5] *(if known)*	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation[6]
	10.	EP 0 255 824 B1	01-24-1990	Norsk Hydro A.S.		
	11.	WO 90/12509	11-01-1990	Hoche		Abstract; English equivalent

NONPATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation[6]
	12.	ACKMAN, R.G. et al., "The "basic" fatty acid composition of Atlantic fish oils: Potential similarities useful for enrichment of polyunsaturated fatty acids by urea complexation," *J. Am. Oil. Chem. Soc.* (1988) vol. 65, pp. 136-138.	
	13.	Azhgikhin,I.S. et al., "Obtainment of an esters concentrate of the eicosapentaenoic and decosapentaenoic as a possible substitute of arachiden and Itenol," Pansovietic Institute, Moscow, dated March 14, 1978.	Yes
	14.	BANG, H.O. et al., "Plasma lipid and lipoprotein pattern in Greenlandic West-coast Eskimos," *Lancet* (1971) vol. 1, pp. 1143-1145.	
	15.	BRONSGEEST-SCHOUTE, H.C. et al., "The effect of various intakes of ω3 fatty acids on the blood lipid composition in healthy human subjects," *Am. J. Clin. Nutr.* (1981) vol. 34, pp. 1752-1757.	
	16.	CONNOR, W.E., "Effects of omega-3 fatty acids in hypertriglyceridemic states," *Seminars in Thrombosis and Hemostasis* (1988) vol. 14, pp. 271-284.	
	17.	DATABASE WPI: Week 199010, Derwent Publications Ltd., JP 2025447.	
	18.	EPAX product information (6 pages)	
	19.	ERITSLAND, J. et al., "Effects of highly concentrated omega-3 polyunsaturated fatty acids and acetylsalicylic acid, alone and combined, on bleeding time and serum lipid profile," *J. Oslo City Hosp.* (1989), vol. 39, pp. 97-101.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.D.C

IDS Form PTO/SB/08: Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				*Application Number*	10/517,812
				Filing Date	December 14, 2004
				First Named Inventor	Harald BREIVIK et al.
(Use as many sheets as necessary)				*Art Unit*	1621
				Examiner Name	Deborah D. CARR
Sheet	2	of	3	*Attorney Docket Number*	10260.0006-00000

NONPATENT LITERATURE DOCUMENTS			
	20.	ERITSLAND, J. et al., "The effect of Omacor™ in patients with hypertriglyceridaemia having undergone coronary artery bypass grafting," Final Report, Pronova Biocare, 1994.	
	21.	"Fish oil, rich in omega-3-acids," European Pharmacopoeia 5.0 (2004) pp. 1595-1598.	
	22.	HARRIS, W.S. et al., "The comparative reductions of the plasma lipids and lipoproteins by dietary polyunsaturated fats: Salmon oil versus vegetable oils," *Metabolism* (1983), vol. 32, pp. 179-184.	
	23.	HIRAI, A. et al., "Effect of oral administration of highly purified eicosapentaenoic acid and docosahexaenoic acid on platelet function and serum lipids in hyperlipidemic patients," *Adv. Prostag. Thromb. L.* (1989) vol. 19, pp. 627-631.	
	24.	HOLUB et al., "Alterations in molecular species of cholesterol esters formed via plasma lecithin - cholesterol acyltransferase in human subjects consuming fish oil," *Atherosclerosis* (1987) vol. 66, pp. 11-18.	
	25.	JOSEPH, J., Ed. "Biomedical Test Materials Program: Production Methods and Safety Manual," NOAA Technical Memorandum NMFS-SEFC-234, pp. 1-3, Oct. 1989.	
	26.	KANTHA, S.S., "Dietary effects of fish oils on human health: A review of recent studies," *Yale J. Biol. Med.* (1987) vol. 60, pp. 37-44.	
	27.	KOBATAKE, Y. et al., "Dietary effect of ω-3 type polyunsaturated fatty acids on serum and liver lipid levels in rats," *J. Nutr. Sci. Vitaminol.* (1983) vol. 29, pp. 11-21.	
	28.	KOBATAKE, Y. et al., "Differential effects of dietary eicosapentaenoic and docosahexaenoic fatty acids on lowering of triglyceride and cholesterol levels in the serum of rats on hypercholesterolemic diet," *J. Nutr. Sci. Vitaminol.* (1984) vol. 30, pp. 357-372.	
	29.	LARSEN, L.N. et al., "Heneicosapentaenoate (21:5n-3): Its incorporation into lipids and its effects on arachidonic acid and eicosanoid synthesis," *Lipids* (1997) vol. 32, pp. 707-714.	
	30.	LEAF, A. et al., "Cariovascular effects of n-3 fatty acids," *New Eng. J. Med.* (1988) vol. 318, pp. 549-557.	
	31.	Lovaza™ marketing information (2 pages)	
	32.	Maxepa® product information (3 pages)	
	33.	Medline Plus, "Triglycerides," U.S. National Library of Medicine and National Institutes of Health, 2008.	
	34.	MEHTA, J.T. et al., "Dietary supplementation with omega-3 polyunsaturated fatty acids in patients with stable coronary heart disease," *Am. J. Med.* (1988) vol. 84, pp. 45-52.	
	35.	MORISAKI, N. et al., "In vivo effects of cis-5,8,11,14,17-20:5 (n-3) and cis-4,7,10,13,16,19-22:6(n-3) on serum lipoproteins, platelet aggregation, and lipid metabolism in the aorta of rats," *Tohoku J. Exp. Med.* (1983) vol. 141, pp. 397-405.	
	36.	MUELLER, B.A. et al., "Biological mechanisms and cardiovascular effects of omega-3 fatty acids," *Clin. Pharmacy* (1988) vol. 7, pp. 795-807.	
	37.	NESTEL, P.J. et al., "Suppression by diets rich in fish oil of very low density lipoprotein production in man," *J. Clin. Invest.* (1984) vol. 74, pp. 82-89.	
	38.	PHILLIPSON, B.E. et al., "Reduction of plasma lipids and lipoproteins in hyperlipidemic patients by dietary w-3 fatty acids," *Am. J. Clin. Nutr.* (1981) vol. 34, p. 629.	
	39.	RATNAYAKE, W.M.N. et al., "Preparation of omega-3 PUFA concentrates from fish oils via urea complexation," *Fat Sci. Technol.* (1988), vol. 90, pp. 381-386.	
	40.	Rote Liste, Eicosapen information, 1987.	No
	41.	SANDERS, T.A.B., "The importance of eicosapentaenoic and docosahexaenoic acids," Ch. 7, pp. 101-116, in *The Role of Fats in Human Nutrition*, F.B. Padley et al., Eds., Ellis Horwood Ltd., Chichester, England, 1985.	
	42.	SANDERS, T.A.B. et al., "A comparison of the influence on plasma lipids and platelet function of supplements of ω3 and ω6 polyunsaturated fatty acids," *Br. J. Nutr.* (1983) vol. 50, pp. 521-529.	
	43.	SANDERS, T.A.B. et al., "The influence of different types of ω3 polyunsaturated fatty acids on blood lipids and platelet function in healthy volunteers," *Clinical Science* (1983) vol. 64, pp. 91-99.	
	44.	SAYNOR, R. et al., "The long-term effect of dietary supplementation with fish lipid concentrate on serum lipids, bleeding time, platelets and angina," *Atherosclerosis* (1984) vol. 50, pp. 3-10.	
	45.	SIMONS, L.A. et al., "On the effects of dietary n-3 fatty acids (Maxepa) on plasma lipids and lipoproteins in patients with hyperlipidaemia," *Atherosclerosis* (1985) vol. 54, pp. 75-88.	
	46.	SIMOPOULOS, A.P., "Omega-3 fatty acids from fish and fish oils: Nutritional and health effects," *Epitheoresе Klinikes Farmakologias Kai Farmakokinetikes, Int. Ed.* (1987) vol. 1, pp. 23-31.	
	47.	SMITH, P. et al., "Influence of highly concentrated n-3 fatty acids on serum lipids and hemostatic variables in survivors of myocardial infarction receiving either oral anticoagulants or matching placebo," *Thromb. Res.* (1989) vol. 53, pp. 467-474.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.D.C

IDS Form PTO/SB/08: Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 3 | of | 3

Complete if Known	
Application Number	10/517,812
Filing Date	December 14, 2004
First Named Inventor	Harald BREIVIK et al.
Art Unit	1621
Examiner Name	Deborah D. CARR
Attorney Docket Number	10260.0006-00000

NONPATENT LITERATURE DOCUMENTS			
	48.	SWANSON, D.R., "Fish oil, Raynaud's Syndrome, and undiscovered public knowledge," *Perspect. Biol. Med.* (1986) vol. 30, pp. 7-18.	
	49.	TURCHETTO, E. et al., "Protective role of vitamin E on essential fatty acids," *Acta Vitaminol. Enzymol.* (1982) vol. 4, pp. 267-277.	Abstract
	50.	VON LOSSONCZY, T.O. et al., "The effect of a fish diet on serum lipids in healthy human subjects," *Am. J. Clin. Nutr.* (1978) vol. 31, pp. 1340-1346.	

Examiner Signature	/Deborah D Carr/	Date Considered	10/08/2009

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.D.C./